Clinical medicine

Traditional Wound Management Market Size Worth $7.7 Billion By 2028: Grand View Research, Inc.

Tuesday, March 2, 2021 - 9:05am

SAN FRANCISCO, March 2, 2021 /PRNewswire/ --The global traditional wound management market size isexpected to reach USD 7.7 billion by2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 2, 2021 /PRNewswire/ --The global traditional wound management market size isexpected to reach USD 7.7 billion by2028, according to a new report by Grand View Research, Inc.
  • The market is expected to expand at a CAGR of 3.7% from 2021 to2028.
  • The rising incidence of chronic diseases, increasing number of accidents, and rising number of ambulatory surgery centers (ASCs) are the key driving factors for the market.
  • Grand View Research has segmented the global traditional wound management market on the basis of product, application, end-use and region:
    Traditional Wound Management Product Outlook (Revenue, USD Million, 2016 - 2028)

Traditional Wound Management Market Size Worth $7.7 Billion By 2028: Grand View Research, Inc.

Tuesday, March 2, 2021 - 9:05am

SAN FRANCISCO, March 2, 2021 /PRNewswire/ --The global traditional wound management market size isexpected to reach USD 7.7 billion by2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, March 2, 2021 /PRNewswire/ --The global traditional wound management market size isexpected to reach USD 7.7 billion by2028, according to a new report by Grand View Research, Inc.
  • The market is expected to expand at a CAGR of 3.7% from 2021 to2028.
  • The rising incidence of chronic diseases, increasing number of accidents, and rising number of ambulatory surgery centers (ASCs) are the key driving factors for the market.
  • Grand View Research has segmented the global traditional wound management market on the basis of product, application, end-use and region:
    Traditional Wound Management Product Outlook (Revenue, USD Million, 2016 - 2028)

DGAP-News: Newly founded biotech company ActiTrexx receives funding of € 3.5 million to develop cell therapy against transplant rejection

Tuesday, March 2, 2021 - 8:02am

The company develops ATreg, a cell therapy based on activated regulatory T cells that are stimulated using a proprietary process, for the treatment of transplant rejection, primarily in the field of stem cell transplantation, and autoimmune disorders.

Key Points: 
  • The company develops ATreg, a cell therapy based on activated regulatory T cells that are stimulated using a proprietary process, for the treatment of transplant rejection, primarily in the field of stem cell transplantation, and autoimmune disorders.
  • The product candidate is in advanced preclinical development and showed unique efficacy in the treatment of GvHD in relevant proof-of-concept studies.
  • www.actitrexx.de
    As a subsidiary of LBBW, LBBW Venture Capital GmbH is the "Center of Competence" for venture capital and technology investments.
  • Since 1998, it has been offering venture capital financing for technology-oriented companies, mainly in the fields of industrial technologies, IT and life sciences.

Masimo Announces CE Marking of the Rad-G™ with Temperature

Tuesday, March 2, 2021 - 7:00am
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210301006115/en/
    Masimo Rad-G with Temperature (Photo: Business Wire)
    The infrared thermometry offered by Rad-G with Temperature provides a host of benefits.
  • With the addition of temperature measurement, Rad-G is more versatile than ever, streamlining the assessment of multiple key vital signs.
  • Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation platform, and include Iris Gateway, iSirona, Patient SafetyNet, Replica, Halo ION, UniView, UniView :60, and Masimo SafetyNet.
  • Published clinical studies on pulse oximetry and the benefits of Masimo SET can be found on our website at http://www.masimo.com .

Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences

Tuesday, March 2, 2021 - 7:00am

Transgenes programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

Key Points: 
  • Transgenes programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
  • With Transgenes myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual.
  • The myvac approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
  • With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ - New Innovative Treatment for Irritable Bowel Syndrome with Constipation

Tuesday, March 2, 2021 - 12:04am

MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (Knight) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

Key Points: 
  • MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (Knight) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availability of IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
  • In the clinical development of IBSRELA diarrhea was the most common adverse event reported by patients often occurring during the first week of treatment.
  • Even with the current therapeutic options, many patients suffering from constipation predominant irritable bowel syndrome remain dissatisfied with the current treatments available.
  • Dr. Louis Liu has received honoraria from Knight Therapeutics Inc. as a consulting physician relating to medical advisory board participation.

Karmanos Cancer Institute Recognizes March as Colorectal Cancer Awareness Month

Monday, March 1, 2021 - 10:15pm

DETROIT, March 1, 2021 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute, along with cancer centers and other organizations across the nation, recognizes March as Colorectal Cancer Awareness Month.

Key Points: 
  • DETROIT, March 1, 2021 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute, along with cancer centers and other organizations across the nation, recognizes March as Colorectal Cancer Awareness Month.
  • Colorectal cancer is the third most common cancer in both men and women; however, there are a variety of screening tests available to detect colorectal cancer.
  • To learn more about colorectal cancer screening at Karmanos, visit https://www.karmanos.org/karmanos/colon-cancer-screening
    At Karmanos, colorectal cancer is treated by the Gastrointestinal & Neuroendocrine Tumors Multidisciplinary Team, which includes surgical oncologists, medical oncologists, radiologists, pathologists, pharmacists, dietitians, social workers and genetic counselors.
  • Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment and compassion.

STRATA Skin Sciences, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monday, March 1, 2021 - 10:35pm

STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.

Key Points: 
  • STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions.
  • Its products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
  • The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatment to vitiligo patients.
  • The Company is a leader in dermatology in-clinic business generation for its partners.

Physician Growth Partners Advises Kellis Eye & Laser Center on Partnership With Ridgemont-Backed Sunvera Group

Monday, March 1, 2021 - 9:41pm

CHICAGO, March 1, 2021 /PRNewswire/ --Physician Growth Partners ("PGP") is pleased to announce a partnership between Kellis Eye & Laser Center ("KELC") and Sunvera Group ("Sunvera"), a portfolio company of Ridgemont Equity Partners ("Ridgemont").

Key Points: 
  • CHICAGO, March 1, 2021 /PRNewswire/ --Physician Growth Partners ("PGP") is pleased to announce a partnership between Kellis Eye & Laser Center ("KELC") and Sunvera Group ("Sunvera"), a portfolio company of Ridgemont Equity Partners ("Ridgemont").
  • Established by Dr. Augustine Kellis in 1994, Kellis Eye & Laser Center is the premier provider of comprehensive eye care services in the greater Northern Ohio market, including cataract surgery, glaucoma and retinal disease management, and general optometry.
  • Physician Growth Partners served as the exclusive transaction advisor to Kellis Eye & Laser Center in its evaluation, negotiation, and execution of this transaction.
  • "Michael Kroin and the PGP Team, including Thomas Mumford and Nick Davis, did a phenomenal job helping Kellis Eye & Laser Center navigate the private equity landscape.

Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences

Monday, March 1, 2021 - 9:01pm

Tumor infiltrating lymphocyte (TIL) therapy uses a patients own immune cells to attack cancer.

Key Points: 
  • Tumor infiltrating lymphocyte (TIL) therapy uses a patients own immune cells to attack cancer.
  • TIL cells are extracted from a patients own tumor tissue, expanded through a proprietary process, and infused back into the patient.
  • Upon infusion, TIL reach tumor tissue, where they attack cancer cells.
  • The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer.